

Published in final edited form as:

J Neurochem. 2012 March ; 120(5): 660–666. doi:10.1111/j.1471-4159.2011.07551.x.

Exogenous seeding of cerebral β -amyloid deposition in β APP-transgenic rats

Rebecca F. Rosen^{1,^}, Jason J. Fritz^{2,3,^}, Jeromy Dooyema¹, Amarallys F. Cintron¹, Tsuyoshi Hamaguchi^{4,5}, James J. Lah^{2,3}, Harry Levine III⁶, Mathias Jucker^{4,5}, and Lary C. Walker^{1,3}

¹Yerkes National Primate Research Center, Emory University, Atlanta, GA, 30329 USA

²Department of Neurology, Emory University, Atlanta, GA, 30329 USA

³Center for Neurodegenerative Disease, Emory University, Atlanta, GA, 30329 USA

⁴Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany

⁵DZNE, German Center for Neurodegenerative Diseases, 72076 Tübingen, Germany

⁶Sanders-Brown Center on Aging, Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536 USA

Abstract

Deposition of the $A\beta$ peptide in senile plaques and cerebral $A\beta$ angiopathy can be stimulated in $A\beta$ -precursor protein-transgenic mice by the intracerebral injection of dilute brain extracts containing aggregated $A\beta$ seeds. Growing evidence implicates a prion-like mechanism of corruptive protein templating in this phenomenon, in which aggregated $A\beta$ itself is the seed. Unlike prion disease, which can be induced *de novo* in animals that are unlikely to spontaneously develop the disease, previous experiments with $A\beta$ seeding have employed animal models that, as they age, eventually will generate $A\beta$ lesions in the absence of seeding. In the present study, we first established that a transgenic rat model expressing human $A\beta$ -precursor protein (APP21 line) does not manifest endogenous deposits of $A\beta$ within the course of its median lifespan (30 months). Next, we injected 3-month-old APP21 rats intrahippocampally with dilute Alzheimer brain extracts containing aggregated $A\beta$. After a 9-month incubation period, these rats had developed senile plaques and cerebral $A\beta$ angiopathy in the injected hippocampus, whereas control rats remained free of such lesions. These findings underscore the co-dependence of agent and host in governing seeded protein aggregation, and show that cerebral $A\beta$ -amyloidosis can be induced even in animals that are relatively refractory to the spontaneous origination of parenchymal and vascular deposits of $A\beta$.

Keywords

Alzheimer; amyloid; prion; proteopathy; senile plaques; transgenic rat

A pivotal occurrence in the development of Alzheimer's disease (AD) is the self-assembly and accumulation of the β -amyloid ($A\beta$) peptide in the brain (Hardy & Selkoe 2002, Holtzman *et al.* 2011). In $A\beta$ -precursor protein- (APP) transgenic mice, cerebral $A\beta$

Address correspondence and reprint requests to Lary Walker, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA, 30329 USA, lary.walker@emory.edu.

[^]These authors contributed equally

deposition can be stimulated by a single intracerebral injection of dilute brain extract containing aggregated A β (Kane *et al.* 2000, Meyer-Luehmann *et al.* 2006, Eisele *et al.* 2009, Eisele *et al.* 2010, Watts *et al.* 2011). Mechanistically, this induction, or *seeding*, of A β -deposition resembles the transmission of prion disease (Sigurdsson *et al.* 2002, Walker *et al.* 2006a, Soto *et al.* 2006, Walker *et al.* 2002, Walker *et al.* 2006b, Jucker & Walker in press, Langer *et al.* in press) in that a misfolded, aggregated form of A β appears to be the seeding agent (Meyer-Luehmann *et al.* 2006, Jucker & Walker in press). A β deposition also has been shown to be seeded in wild-type marmosets (Baker *et al.* 1994, Ridley *et al.* 2006), a New World monkey that, like all primates that have been studied to date, naturally generates human-sequence A β (Heuer *et al.* in press).

The characteristics of both the seeding agent and the host cortical milieu influence the pathologic signature of exogenous A β seeds (Meyer-Luehmann *et al.* 2006). Wild-type mice and rats, in which A β differs from that in humans by three amino acids (Otvos Jr *et al.* 1993), do not naturally generate senile (A β) plaques or cerebral A β -angiopathy (CAA), nor do they demonstrate seeded A β deposition (Kane *et al.* 2000, Meyer-Luehmann *et al.* 2006). The experimental animals successfully used for A β -seeding studies thus far – APP-transgenic mice and marmosets – do express human-sequence A β , and, with age, all of them eventually will develop A β -plaques and/or CAA in the absence of seeding. In contrast, prion disease can be transmitted to animals that are otherwise unlikely to manifest disease within their lifetimes. Thus, it is possible that prion disease and A β -amyloidosis differ in that prion disease can be induced in normally refractory hosts, whereas the seeded induction of A β aggregation simply involves the acceleration of a process that will eventually become manifest, in the absence of seeding, as the host animals age. In this study, we sought to determine whether A β deposition can be induced in a host that is relatively resistant to the endogenous generation of plaques and CAA. To achieve this, we chose an APP-transgenic rat model (APP21; (Agca *et al.* 2008)) that expresses human A β but does not generate endogenous A β lesions during the course of its median lifespan. We show that the intracerebral delivery of dilute cortical extracts from AD patients to 3-month old APP21 rats stimulates the formation of A β -plaques and CAA by 12 months of age.

Material and methods

Subjects

The APP21 transgenic rat line was produced on the inbred Fischer-344 strain (Agca *et al.* 2008). The human APP transgene includes the ‘Swedish’ (Swe) double mutation (K670N-M671L) along with the ‘Indiana’ (Ind) single AD mutation (V642F). The transgene is driven by the ubiquitin-C promoter, and the overall expression pattern of transgenic APP is similar to that of endogenous rat APP. Homozygous APP21 rats express ~2.9-fold more APP mRNA than do wild-type rats, and transgenic (human-sequence) A β is readily detectable in brain and in serum (Agca *et al.* 2008). To determine whether normal APP21 rats develop A β deposits with age, we analyzed homozygous APP21 rats (males and females) at 1, 3, 6, 12, 18, 24 and 30 months of age. 18-24 rats per group were studied in the groups ranging in age from 1-18 months, but due to age-associated attrition, only 10 rats were available for analysis at 24 months, and 8 rats at 30 months of age.

For the A β -seeding studies, eleven male, homozygous APP21-transgenic rats and 5 male, non-transgenic Fischer-344 control rats were studied (Table 1). Only male rats were used in the seeding studies to reduce variability caused by potential gender-related differences in A β deposition (Callahan *et al.* 2001). All rats were maintained under specific pathogen-free conditions, and the research protocols were approved by the institutional animal care and use committee.

Preparation of donor brain tissue seeding extracts

Neocortical tissue samples were obtained at autopsy from clinically and histopathologically confirmed AD cases, as well as an aged, non-demented patient whose brain was free of AD lesions. The samples were immediately frozen at -80°C until use. The tissue extracts were prepared as previously described (Kane et al. 2000, Meyer-Luehmann et al. 2006). Briefly, the cortical blocks were homogenized at 10% or 20% (w/v) in PBS, vortexed, probe-sonicated 3×5 s with a Fisher Sonic Dismembrator 100 (setting 5) and centrifuged at $3000 \times G$ for 5 min. The clear supernatant was collected, divided into aliquots, and frozen. Total A β levels in the injectates were estimated by immunoassay to be ~ 0.5 -2 ng/ μl .

Stereotaxic injection of brain extracts

The rats were anesthetized with a mixture of ketamine (80mg/kg) and xylazine (8mg/kg) and maintained with 55mg/kg ketamine as needed. Seven APP21 rats and the five non-transgenic control rats were injected bilaterally with 5 μl of clear, 10% AD extract into the dorsal hippocampus (interaural +5.86mm; lateral ± 1.8 mm; ventral 3.4mm (Paxinos & Watson 1998). Injections were made with a Hamilton syringe at the rate of 2.5 μl /minute, and the syringe was left in place for an additional two minutes before slow withdrawal. In two additional transgenic rats, a 20% AD cortical extract (5 μl) was similarly injected. As further controls, one rat received 5 μl of 10% extract and one received 5 μl of 20% extract from the brain of a 75 year-old nondemented control patient (histopathologically confirmed non-AD).

Tissue processing and analysis

Unseeded APP21 rats—The unseeded APP21 rats were transcardially perfused with PBS under deep sodium pentobarbital anesthesia (200mg/kg). One hemisphere for immunohistochemistry then was immersion-fixed in phosphate-buffered 4% paraformaldehyde for 4 hours, cryoprotected in 30% sucrose, frozen, and stored at -80°C until analysis. The other hemisphere was frozen (unfixed) with dry ice and stored at -80°C for analysis by immunoblot. In the 24- and 30-month old rats, only immunohistochemical analysis was performed on whole fixed brains due to age-related attrition of subjects at these ages.

Immunoblotting—Unfixed hemispheres from a subset of unseeded rats at 3, 9 and 18 months of age were analyzed by immunoblotting as previously described (Rosen *et al.* 2010). Briefly, the samples were homogenized in nine volumes of PBS, vortexed, probe-sonicated (10×0.5 sec), centrifuged at $5,000 \times g$ for 10 min at 4°C , and supernatants were stored at -80°C until use. Total protein in the samples was quantified with the bicinchoninic acid (BCA) assay. 76 μg of total protein per sample were run on a 10-20% Tricine gel (Invitrogen) and blotted onto a nitrocellulose membrane. The membrane was boiled for 5 min in 1xPBS and probed with antibody 6E10 to A β (1:500). The secondary antibody was horseradish peroxidase-conjugated anti-mouse IgG (1:10,000). For signal detection, Super Signal West Pico electrochemiluminescence (Fisher Scientific) was used, after which the membrane was exposed to Kodak MR Biomax film (Kodak, New Haven, CT, USA).

Extract-injected rats—To optimize the sensitivity of detection, and to enable the localization and characterization of seeded A β deposits, whole brains from all cortical extract-injected rats were analyzed by immunohistochemistry. The rats were sacrificed under deep sodium pentobarbital anesthesia (200mg/kg) by transcardial perfusion with PBS (pH 7.4) followed by phosphate-buffered 4% paraformaldehyde. The brains were removed, post-fixed for 24-48 hours in phosphate-buffered 4% paraformaldehyde (4°C), cryoprotected

in phosphate-buffered 30% sucrose, blocked, frozen on dry ice, and then stored at -80°C until processing.

Histochemistry—For histochemical analysis, brains were cut on a cryostat at $40\mu\text{m}$ thickness, and sections were stained with antibodies 6E10 (1:15,000; [Covance, Princeton, NJ]); 4G8 (1:10,000; mouse IgG2b monoclonal antibody [Covance] raised against residues 17-24 of A β); and rabbit polyclonal antibodies R361 and R398 (both at 1:15,000; [courtesy of Dr. Pankaj Mehta, Institute for Basic Research on Developmental Disabilities, Staten Island, NY] raised against synthetic A β 32-40 and A β 33-42, respectively)(see Rosen et al., 2008 for antibody details). β -amyloid load (percent area of the hippocampus occupied by A β -immunoreactive deposits) was determined on immunostained sections using point-counting methods (Mouton 2011). Additional sections were stained with thioflavin-S, and some were lightly counterstained with hematoxylin. Sections were photographed with a Spot Flex digital camera (Diagnostic Instruments, Sterling Heights, MI, USA) attached to a Leica DMLB microscope.

Statistical analysis

Values are expressed as means \pm SEM. Because A β deposits were not found in normal, unseeded APP21 rats or in extract-injected non-transgenic rats (below), group differences in the induction of A β deposits were assessed using the nonparametric Fisher's Exact Test (Graphpad Software). The significance threshold was set at $p \leq 0.05$, two-tailed.

Results

Normal (unseeded) APP21 rats do not spontaneously generate cerebral A β deposits

The median life-span of *ad lib*-fed Fischer-344 rats is slightly under 30 months (Ghirardi *et al.* 1995). To determine whether APP21 rats spontaneously generate A β plaques or CAA within this period, we analyzed unseeded, homozygous APP21 rats at 1, 3, 6, 12, 18, 24 and 30 months of age. Antibody 6E10 (which is highly selective for human-sequence A β) recognized normal-appearing intracellular human A β /APP in the transgenic rats at all ages, but none of the unseeded APP21 rats developed extracellular A β plaques or CAA at any age (Figure 1). Immunoblot analysis of fresh-frozen cortical samples from a subset of APP21 and wild-type rats at 3, 9 and 18 months of age detected strong bands corresponding to APP (~ 100 KDa) solely in APP21 rats (Figure 1C). A β was below the level of detection at these ages.

A β deposition can be exogenously seeded in APP21 rats

Nine months following the intrahippocampal infusion of AD cortical extracts into three month-old APP21 rats, all animals ($n=4$) showed seeded induction of A β deposition in the hippocampal formation (Figure 2A,B), whereas the AD extract-injected non-transgenic rats ($n=5$) were devoid of A β deposition (Figure 2D) ($p=0.008$, Fisher's Exact Test). The seeded A β deposits were strongly immunoreactive with antibodies 6E10, 4G8, and R398, but they were negative or only weakly stained with antibody R361 (to A β 40) and with thioflavin-S, indicating that the seeded deposits consisted primarily of diffuse aggregates of A β 42. Three-month-old transgenic APP21 rats injected with cortical extract from a control (non-AD) case ($n=2$) were negative after a 9-month incubation period.

Five additional APP21 rats (again 3 months old) were injected with AD brain extract and allowed to incubate for 3 months or 6 months. Two animals developed very light A β -immunoreactivity in the immediate vicinity of the injection site, one in the 6 month group and one in the 3 month group (Figure 2C). The other 3 rats assessed at these timepoints were negative.

Discussion

Previous studies with APP-transgenic mice have shown that A β deposition can be stimulated by the introduction of dilute brain extracts containing aggregated A β (Kane et al. 2000, Meyer-Luehmann et al. 2006, Eisele et al. 2009, Watts et al. 2011, Langer et al. in press). However, the host models used in these studies eventually will develop A β -plaques and CAA with age, so it is uncertain whether animals that are less likely to generate such lesions with age also are susceptible to seeded A β deposition. In the present study, we report that senile plaques and cerebral A β angiopathy can be induced in an APP-transgenic rat model that does not spontaneously form such deposits in the brain during the course of its median lifespan. While we cannot exclude the possibility that APP21 rats that survive into extreme old age (>30 months) would eventually manifest A β deposition, our findings indicate that protein aggregation can be exogenously precipitated in an animal model that is relatively resistant to the endogenous generation of A β lesions. This conclusion is strengthened by a recent report that A β deposition can be induced *de novo* in transgenic mice expressing wild-type human APP (Morales *et al.* in press).

Our findings reinforce the importance of host factors in governing the response of the brain to exogenous, A β -rich brain extracts. In APP-transgenic mice, the type of host has been shown to influence both the phenotype of the seeded lesions and the timecourse of lesion formation (Meyer-Luehmann et al. 2006). In general, transgenic mice that display a relatively aggressive emergence of endogenous plaques and/or CAA also respond more rapidly to the exogenous introduction of corruptive seeds (Meyer-Luehmann et al. 2006). In the APP21 transgenic rats that we investigated, substantial A β deposition was only apparent after 9 months of incubation, with little seeded deposition at 3 or 6 months post-injection. The importance of the host in modulating the timecourse of seeding is underscored by studies of marmosets (Baker et al. 1994, Maclean *et al.* 2000, Ridley et al. 2006). In the colony of marmosets investigated by this group, endogenous A β amyloidosis begins to materialize after 11 years of age (Ridley et al. 2006), and the seeded augmentation of A β load only is apparent after an incubation period of 5-6 years (Baker et al. 1994). Taken together, these studies in nonhuman primates and transgenic rodents indicate that A β deposition can be exogenously induced in animals that generate human-sequence A β , but that the lag time preceding the emergence of the lesions is proportional to the timecourse of endogenous A β deposition in the host.

Though they are incomplete models of human disease, transgenic mice expressing disease-related proteins have energized the experimental investigation of AD and other neurodegenerative disorders (Jucker 2010, Ashe & Zahs 2010, Wisniewski & Sigurdsson 2010, Harvey *et al.* 2011). In mice, the expression of transgenic, usually mutant, human APP typically results in the predictable development of senile plaques and/or CAA by a model-specific age (LeVine III & Walker 2006, Morrisette *et al.* 2009, Jucker 2010). The rate and degree of endogenous β -amyloid formation varies considerably among models, however, and is influenced by such factors as genetic background, gender, APP expression levels, the presence and type of pathogenic mutations, and the co-expression of other transgenes such as an AD-mutant form of presenilin-1, a protein that enhances the overproduction of A β peptides from full length APP (Hock *et al.* 2009, Jucker 2010). Transgenic rat models of AD pathology still are relatively uncommon, but they have certain advantages over mice owing to their larger size, unique genetics, and well-studied behavioral characteristics (Tesson *et al.* 2005). Compared to APP-transgenic mice, many APP-transgenic rats have not readily developed endogenous cerebral β -amyloidosis (Echeverria *et al.* 2004, Ruiz-Opazo *et al.* 2004, Folkesson *et al.* 2007, Clarke *et al.* 2007), although one APP_{Swe/Ind} transgenic rat develops plaques beginning around 6 months of age (Leon *et al.* 2010), and, as in mice, the co-expression of presenilin-1 along with APP can

stimulate the robust deposition of A β (Flood *et al.* 2007, Liu *et al.* 2008). The exogenous seeding paradigm might be employed to stimulate lesion formation in these resistant models, to synchronize the onset and progression of protein aggregation, and to evaluate the effects of seeding on neuronal integrity and behavior.

In summary, we show that A β deposition can be exogenously seeded in an APP-transgenic rat that is refractory to endogenous A β deposition during the course of its median lifespan. These findings in a new model and species support growing evidence that A β aggregation can be induced in the brain by a process of corruptive protein templating (Jucker & Walker in press), a molecular mechanism that may underlie the pathogenesis of numerous neurodegenerative diseases (Sigurdsson *et al.* 2002, Walker *et al.* 2002, Walker *et al.* 2006b, Soto *et al.* 2006, Jucker & Walker in press). The results also confirm that the expression of human-sequence A β by the host is necessary for seeding by A β -rich brain extracts, but also that other, as yet unidentified, host factors govern the lag phase preceding the appearance of senile plaques and CAA. At present, there is no evidence that AD *per se* is transmissible in the same manner as is prion disease. However, a more complete understanding of the determinants of protein seeding and accumulation in different hosts could inform therapeutic strategies to interrupt the proteopathic cascade in human neurodegenerative diseases.

Acknowledgments

This work was supported by NIH P51RR-000165, P50AG025688, University of Kentucky Faculty Support Grant 1012101660, the CART Foundation, the Competence Network on Degenerative Dementias (BMBF-01GI0705) and the BMBF in the frame of ERA-Net NEURON (MIPROTRAN). We gratefully acknowledge helpful discussions with Dr. Marla Gearing (Emory University).

Abbreviations used

Aβ	amyloid- β (β -amyloid)
AD	Alzheimer's disease
APP	A β -precursor protein
BCA	bicinchoninic acid
CAA	cerebral amyloid- β angiopathy
IgG	immunoglobulin G
kDa	kilodalton(s)
Ind	'Indiana' AD mutation
PBS	phosphate-buffered saline
SEM	standard error of the mean
Swe	'Swedish' AD double mutation

References

- Agca C, Fritz JJ, Walker LC, Levey AI, Chan AW, Lah JJ, Agca Y. Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically. *BMC Neurosci.* 2008; 9:28. [PubMed: 18302776]
- Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. *Neuron.* 2010; 66:631–645. [PubMed: 20547123]

- Baker HF, Ridley RM, Duchon LW, Crow TJ, Bruton CJ. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. *Molecular Neurobiology*. 1994; 8:25–39. [PubMed: 8086126]
- Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. *Am J Pathol*. 2001; 158:1173–1177. [PubMed: 11238065]
- Clarke J, Thornell A, Corbett D, Soininen H, Hiltunen M, Jolkkonen J. Overexpression of APP provides neuroprotection in the absence of functional benefit following middle cerebral artery occlusion in rats. *Eur J Neurosci*. 2007; 26:1845–1852. [PubMed: 17897395]
- Echeverria V, Ducatenzeiler A, Alhonen L, et al. Rat transgenic models with a phenotype of intracellular Abeta accumulation in hippocampus and cortex. *J Alzheimers Dis*. 2004; 6:209–219. [PubMed: 15201476]
- Eisele YS, Bolmont T, Heikenwalder M, et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. *Proc Natl Acad Sci U S A*. 2009; 106:12926–12931. [PubMed: 19622727]
- Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally Applied A{beta}-Containing Inoculates Induce Cerebral {beta}-Amyloidosis. *Science*. 2010
- Flood DG, Lin YG, Lang DM, Trusko SP, Hirsch JD, Savage MJ, Scott RW, Howland DS. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. *Neurobiology of Aging*. 2007
- Folkesson R, Malkiewicz K, Kloskowska E, et al. A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation. *Biochemical and Biophysical Research Communications*. 2007; 358:777–782. [PubMed: 17506994]
- Ghirardi O, Cozzolino R, Guaraldi D, Giuliani A. Within- and between-strain variability in longevity of inbred and outbred rats under the same environmental conditions. *Exp Gerontol*. 1995; 30:485–494. [PubMed: 8557096]
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*. 2002; 297:353–356. [PubMed: 12130773]
- Harvey BK, Richie CT, Hoffer BJ, Airavaara M. Transgenic animal models of neurodegeneration based on human genetic studies. *J Neural Transm*. 2011; 118:27–45. [PubMed: 20931247]
- Heuer E, Rosen RF, Cintron A, Walker LC. Nonhuman primate models of Alzheimer-like cerebral proteopathy. *Current Pharmaceutical Design*. in press.
- Hock BJ, Lattal KM, Kulnane LS, Abel T, Lamb BT. Pathology associated memory deficits in Swedish mutant genome-based amyloid precursor protein transgenic mice. *Curr Aging Sci*. 2009; 2:205–213. [PubMed: 20021415]
- Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. *Sci Transl Med*. 2011; 3:77sr71.
- Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. *Nat Med*. 2010; 16:1210–1214. [PubMed: 21052075]
- Jucker M, Walker LC. Pathogenic Protein Seeding in Alzheimer's Disease and Other Neurodegenerative Disorders. *Annals of Neurology*. in press.
- Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. *J Neurosci*. 2000; 20:3606–3611. [PubMed: 10804202]
- Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. *J Neurosci*. in press.
- Leon WC, Canneva F, Partridge V, et al. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. *J Alzheimers Dis*. 2010; 20:113–126. [PubMed: 20164597]
- LeVine, H., III; Walker, LC. Models of Alzheimer's disease. In: Conn, PM., editor. *Handbook of Models for Human Aging*. Academic Press; Burlington: 2006. p. 121-134.

- Liu L, Orozco JJ, Planel E, et al. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. *Neurobiol Dis.* 2008; 31:46–57. [PubMed: 18504134]
- Maclean CJ, Baker HF, Ridley RM, Mori H. Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (*Callithrix jacchus*). *J Neural Transm.* 2000; 107:799–814. [PubMed: 11005545]
- Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science.* 2006; 313:1781–1784. [PubMed: 16990547]
- Morales R, Duran-Aniotz C, Castilla J, Estrada L, Soto C. De novo induction of amyloid-beta deposition in vivo. *Mol Psychiatry.* in press.
- Morrisette DA, Parachikova A, Green KN, LaFerla FM. Relevance of transgenic mouse models to human Alzheimer disease. *The Journal of Biological Chemistry.* 2009; 284:6033–6037. [PubMed: 18948253]
- Mouton, PR. *Unbiased Stereology: A Concise Guide.* The Johns Hopkins University Press; Baltimore: 2011.
- Otvos L Jr, Szendrei GI, Lee VM-Y, Mantsch HH. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. *European Journal of Biochemistry.* 1993; 211:249–257. [PubMed: 8425535]
- Paxinos, G.; Watson, C. *The Rat Brain in Stereotaxic Coordinates.* 4th edition. Academic Press; San Diego: 1998.
- Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of beta-amyloidosis in primates. *J Neural Transm.* 2006; 113:1243–1251. [PubMed: 16362635]
- Rosen RF, Tomidokoro Y, Ghiso JA, Walker LC. SDS-PAGE/immunoblot detection of A β multimers in human cortical tissue homogenates using antigen-epitope retrieval. *J Vis Exp.* 2010
- Ruiz-Opazo N, Kosik KS, Lopez LV, Bagamasbad P, Ponce LR, Herrera VL. Attenuated hippocampus-dependent learning and memory decline in transgenic TgAPP^{swe} Fischer-344 rats. *Mol Med.* 2004; 10:36–44. [PubMed: 15502881]
- Sigurdsson EM, Wisniewski T, Frangione B. Infectivity of amyloid diseases. *Trends Mol Med.* 2002; 8:411–413. [PubMed: 12223307]
- Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. *Trends Biochem Sci.* 2006; 31:150–155. [PubMed: 16473510]
- Tesson L, Cozzi J, Menoret S, Remy S, Usal C, Fraichard A, Anegon I. Transgenic modifications of the rat genome. *Transgenic Res.* 2005; 14:531–546. [PubMed: 16245144]
- Walker L, Levine H, Jucker M. Koch's postulates and infectious proteins. *Acta Neuropathol (Berl).* 2006a; 112:1–4. [PubMed: 16703338]
- Walker LC, Bian F, Callahan MJ, Lipinski WJ, Durham RA, LeVine H. Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key? *Amino Acids.* 2002; 23:87–93. [PubMed: 12373522]
- Walker LC, Levine H 3rd, Mattson MP, Jucker M. Inducible proteopathies. *Trends in Neurosciences.* 2006b; 29:438–443. [PubMed: 16806508]
- Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. Bioluminescence imaging of A β deposition in bigenic mouse models of Alzheimer's disease. *Proc Natl Acad Sci U S A.* 2011; 108:2528–2533. [PubMed: 21262831]
- Wisniewski T, Sigurdsson EM. Murine models of Alzheimer's disease and their use in developing immunotherapies. *Biochim Biophys Acta.* 2010; 1802:847–859. [PubMed: 20471477]




Fig. 1. Analysis of senile plaques, CAA and APP in unseeded APP21 rats. **A:** Low magnification overview of a parasagittal section from an unseeded 30-month-old APP21 rat; **B:** Higher magnification of the hippocampal formation and dentate gyrus. Antibody 6E10 detected light immunoreactivity of transgenic (human-sequence) A β /APP in neuronal somata throughout the brain, but no extracellular deposition of A β was seen in any unseeded APP21 rat. Bar in panel B = 200 μ m. **C:** Western blot of cortical homogenates from APP21 and wild-type control rats at three different ages, immunostained with mouse monoclonal antibody 6E10. A preparation of aggregated, synthetic A β 42 (10ng) is in the far left lane as a positive control. In the transgenic rats only, 6E10-immunoreactive bands corresponding to APP (~100kDa) were detected in similar quantities at all 3 ages. A β in all rats was below detection level. The bands at ~17kDa (arrowhead) are nonspecific cross-reactive material.




Figure 2. Seeded deposition of A β in the hippocampus proper and dentate gyrus (**A**), and the subiculum (**B**) of a representative, 12-month old APP21 transgenic rat that had received an intracerebral infusion of dilute AD cortical extract at 3 months of age. Diffuse A β deposits occurred in the walls of blood vessels (black arrow), as sheet-like formations (arrowheads mark A β immunoreactivity in the granule cell layer), and as parenchymal, plaque-like deposits (gray arrow, middle). A mean of $2.3 \pm 0.8\%$ of the area of the dorsal hippocampus was occupied by A β deposits in the 9-month seeded rats. **C**: Light, perivascular A β deposition (arrow) in the hippocampal formation of an APP21 transgenic rat 3 months following infusion of cortical extract. Non-transgenic rats similarly injected (**D**) did not have immunoreactive A β in the hippocampus after 9 months. Antibodies 4G8 (**A**) and 6E10 (**B-D**); Bars = 200 μm .

Table 1

Injectates and incubation times

	Incubation Time (months)		
Injectate	3	6	9
AD	APP21 (n=3)	APP21 (n=2)	APP21 (n=4) Non-tg (n=5)
Non-AD Control			APP21 (n=2)